Search
for
Sort by
Research 361–390 of 1000+
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations
- Iron Chelators in the Management of Autoimmune-Induced Alopecia: A Focus on Hypoxia-Inducible Factor 1 Modulation and Hair Restoration
- 22-Year-Old Male with Several Discrete Patches of Hair Loss
- 63-Year-Old Female with Diffuse Thinning of the Hair
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- Approach to Managing Recalcitrant Alopecia Areata with Combination Therapy: A Series of Five Cases in Black Pediatric Patients
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries
- Alopecia areata and ritlecitinib: Unravelling response trajectories
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
- An ERK-dependent molecular switch antagonizes fibrosis and promotes regeneration in spiny mice ( <i>Acomys</i> )
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
- Emerging treatments in alopecia
- Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment
- Costunolide—A Bioactive Sesquiterpene Lactone with Diverse Therapeutic Potential
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US
- Targeted immunotherapy for hair regrowth and regeneration
- Evolving treatment paradigms in dermatology: Insights from emerging and repurposed therapies
- British Association of Dermatologists living guideline for managing people with alopecia areata 2024
- Acral Vitiligo: A Comprehensive Review of Clinical Features, Pathogenesis, and Novel Therapeutic Advances
- Evaluating Scarring Alopecia Therapies from the Patient Perspective: Knowledge, Barriers to Care, and Treatment Satisfaction
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib